Breast. 2026 May 12;88:104797. doi: 10.1016/j.breast.2026.104797. Online ahead of print.
ABSTRACT
BACKGROUND: Women living with HIV (WLHIV) may present with distinct clinical and laboratory characteristics at the time of breast cancer diagnosis. While previous studies, including multi-country cohorts such as the ABC-DO study, have described baseline patient and tumor features, data on pre-treatment laboratory parameters in routine clinical settings remain limited. This study aimed to characterize baseline clinical and laboratory factors at diagnosis and assess differences by HIV status.
METHODS: We analyzed data from women newly diagnosed with breast cancer at three tertiary hospitals in Tanzania. HIV status was obtained from medical records or provider-initiated testing. Baseline clinical and laboratory variables measured before systemic cancer therapy were evaluated. Multivariable logistic regression was used to identify factors independently associated with HIV status.
RESULTS: Among 425 women with newly diagnosed breast cancer, 47 (11%) were living with HIV. Advanced disease at presentation was common across the cohort. Neutropenia (absolute neutrophil count <1.5 × 109/L) was more frequent among WLHIV than among women without HIV (15% vs 3%) and remained independently associated with HIV status (adjusted odds ratio [aOR] 3.52, 95% confidence interval [CI] 1.26-9.79).
CONCLUSIONS: WLHIV more frequently presented with neutropenia and advanced disease at diagnosis. By identifying clinically relevant differences in hematologic status are detectable at presentation using routinely collected data, this study addresses a key gap in real-world evidence from sub-Saharan Africa. These findings provide clinically actionable insight into baseline patient status at entry into cancer care and may inform early clinical assessment and supportive care planning in resource-constrained settings.
PMID:42127480 | DOI:10.1016/j.breast.2026.104797
